Kestra Medical Technologies, Ltd. officer and director Brian Daniel Webster filed a Form 144 notice of proposed sale on November 18, 2026, disclosing plans to sell 15,000 shares of common stock through Merrill Lynch on NASDAQ.

Key Highlights

  • Proposed sale: Brian Daniel Webster intends to sell 15,000 shares of Kestra Medical Technologies common stock with an aggregate market value of $426,920.72.
  • Source of shares: The 15,000 shares were acquired on July 14, 2026, via a Performance Stock Issuance granted as part of the issuer equity compensation plan.
  • Shares outstanding: According to the filing, 59,561,795 shares of common stock were outstanding at the time of notice.
  • 10b5-1 plan: The filing indicates a Rule 10b5-1 trading plan or instruction was adopted on July 21, 2026.
  • Prior three-month sales: Webster reported seven separate sales totaling 126,722 shares between July 15, 2026, and October 20, 2026, with combined gross proceeds of $3,156,978.32.
  • Broker: The proposed sale is to be executed through Merrill Lynch, located at 225 Liberty St, New York, NY 10281.

Webster's Proposed Sale and Recent Transaction History at Kestra Medical

According to the Form 144 filing submitted on November 18, 2026, Brian Daniel Webster, who holds the dual roles of officer and director at Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), intends to sell 15,000 shares of the company's common stock. The aggregate market value of the proposed sale is listed as $426,920.72, with an approximate sale date of November 18, 2026. The filing identifies Merrill Lynch as the executing broker.

The filing discloses that the 15,000 shares slated for sale were acquired on July 14, 2026, through a Performance Stock Issuance described as "granted as part of issuer equity compensation plan." Webster also indicated reliance on a Rule 10b5-1 plan or instruction, with an adoption date of July 21, 2026. Kestra Medical Technologies is headquartered at 3933 Lake Washington Blvd NE, Suite 200, Kirkland, Washington 98033, and carries SEC File Number 001-42549.

The filing's three-month sales history section lists seven prior transactions by Webster: 15,000 shares sold on July 15, 2026, for gross proceeds of $336,609.41; 7,857 shares on July 30, 2026, for $178,531.04; 8,948 shares on July 31, 2026, for $202,259.77; 13,017 shares on August 3, 2026, for $311,424.12; 51,900 shares on August 4, 2026, for $1,272,585.45; 15,000 shares on August 17, 2026, for $412,180.90; and 15,000 shares on October 20, 2026, for $443,388.63.

What Was Disclosed

Brian Daniel Webster, an officer and director of Kestra Medical Technologies, Ltd., filed a Form 144 on November 18, 2026, to notify the SEC of a proposed sale of 15,000 common shares acquired via a performance stock issuance, with seven prior sales also reported for the preceding three months.